Hormone therapyFDA-approvedFirst-line
Bicalutamide
How it works
Blocks the action of testosterone on prostate cancer cells, slowing their growth.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, bicalutamide improved survival rates and reduced the risk of cancer progression in patients with advanced prostate cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Prostate Cancer Treatment Study | Prostate Cancer | phase-2 | — | Source → |
| Comparing Two Treatments for Advanced Prostate Cancer | Prostate Cancer | observational | The apalutamide group showed significantly higher CRPC-free probability at 24 months (68.2% vs. 39.8%, p < 0.001) compared to the bicalutamide group. | Source → |
| Bicalutamide Treatment for Advanced Prostate Cancer | Prostate Cancer | observational | Patients at low risk for disease progression had a 5-year OS of 100% and a 10-year OS of 75%. | Source → |
| Cost-effectiveness of rezvilutamide in prostate cancer treatment | Prostate Cancer | phase-3 | The rezvilutamide group showed an expected gain of 2.28 QALYs and an incremental cost of US$60 758.82 compared with the bicalutamide group. | Source → |
| Bicalutamide-Induced Gynecomastia Reversible with Hormone Therapy | Prostate Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.